Novo Nordisk board moves
- Social reports say Novo Nordisk’s chair Helge Lund and five directors are stepping down after a dispute with its owner foundation. (x.com) - Other posts discuss strategic options like splitting businesses, launching an oral GLP‑1 pill, and telehealth pushes. ( ) - The chatter frames a company reorganizing governance and retail-focused access strategies amid rapid GLP‑1 market growth. (x.com)
Novo Nordisk’s 2025 board shake-up was not a rumor: chair Helge Lund and six other directors stepped down after a dispute with the company’s controlling owner. (novonordisk.com) The company said on October 21, 2025 that Lund, vice chair Henrik Poulsen, and five other board members would not stand for election at an extraordinary shareholder meeting on November 14, 2025. Novo Nordisk’s notice named Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, and Martin Mackay among those leaving. (novonordisk.com) At that November 14 meeting, seven directors stepped down and four new members were elected. Novo Nordisk’s 2025 annual report says the board intended to add more independent directors again at the March 2026 annual meeting after the reshuffle left only two of five shareholder-elected directors classified as independent. (novonordisk.com) The ownership structure helps explain why the foundation could force the issue. Novo Holdings, which is wholly owned by the Novo Nordisk Foundation, holds the majority of votes at Novo Nordisk’s general meetings and is required to maintain controlling ownership in the company. (novonordisk.com; novoholdings.dk) This fight landed as Novo Nordisk was trying to defend its lead in obesity drugs, a market growing at unusual speed. The company said 2025 obesity-care sales rose 26% in Danish kroner to DKK 82.3 billion, while the global branded glucagon-like peptide-1 obesity market grew 104% by volume. (novonordisk.com) Novo Nordisk also spent 2025 broadening how it sells those medicines. Its annual report says the company launched a Wegovy pill in the United States, while an investor presentation said U.S. self-pay prescriptions were being filled through NovoCare Pharmacy, retail pharmacies, and telehealth pharmacies. (novonordisk.com; novonordisk.com) That oral drug push had been building for years. Novo Nordisk says semaglutide became the first approved oral glucagon-like peptide-1 treatment for weight management in the U.S. in 2025, after earlier oral semaglutide work in diabetes and obesity trials such as OASIS 1. (novonordisk.com; novonordisk.com) Novo Nordisk’s own strategy documents do not describe a plan to split the company in two. They do show a narrower focus on obesity and diabetes programs, plus a commercial push built around new formats, new channels, and faster reach in a market where Eli Lilly and other rivals are pressing on price, access, and convenience. (novonordisk.com; novonordisk.com) So the clearest reading of the episode is not an unverified social-media purge, but a documented governance reset at a foundation-controlled drugmaker that was already remaking its board, product lineup, and sales channels around the obesity boom. (novonordisk.com; novonordisk.com)
